AREV Life Sciences Global Corp. Stock

Equities

AREV

CA04019J1093

Food Processing

Market Closed - Canadian Securities Exchange 12:06:40 2023-07-11 pm EDT 5-day change 1st Jan Change
0.09 CAD -10.00% Intraday chart for AREV Life Sciences Global Corp. -.--% -.--%
Sales 2021 0.25 0.35 Sales 2022 0.05 0.07 Capitalization 2.05M 2.8M
Net income 2021 - 0 Net income 2022 -1M -1.37M EV / Sales 2021 32,369,123 x
Net cash position 2021 82.57K 113K Net Debt 2022 28.74K 39.28K EV / Sales 2022 42,324,191 x
P/E ratio 2021
-6.13 x
P/E ratio 2022
-1.35 x
Employees 2
Yield 2021 *
-
Yield 2022
-
Free-Float 52.22%
More Fundamentals * Assessed data
Dynamic Chart
AREV Life Sciences Global Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
AREV Life Sciences Global Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
AREV Life Sciences Global Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
AREV Life Sciences Global Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
AREV Life Sciences Global Corp. (CNSX : AREV) cancelled the acquisition of Fiberlab, Inc. CI
AREV Life Sciences Global Corp. cancelled the transaction announced on March 14, 2023 CI
AREV Life Sciences Global Corp. (CNSX : AREV) entered into letter on intent to acquire Fiberlab, Inc for $7 million. CI
AREV Life Sciences Global Corp. announced that it expects to receive CAD 7.548 million in funding CI
AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from Board CI
AREV Life Sciences Global Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
AREV Life Sciences Global Corp. Announces Management Changes CI
AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory Board CI
AREV Life Sciences Global Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
AREV Life Sciences Global Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
AREV Life Sciences Global Corp. Auditor Raises 'Going Concern' Doubt CI
More news
1 year
0.09
Extreme 0.09
0.18
3 years
0.07
Extreme 0.065
0.39
5 years
0.05
Extreme 0.05
2.52
10 years
0.05
Extreme 0.05
3.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 86-08-24
Director of Finance/CFO - 18-02-09
Director/Board Member 69 21-02-22
Members of the board TitleAgeSince
Director/Board Member 69 21-02-22
Director of Finance/CFO - 18-02-09
Chief Executive Officer - 86-08-24
More insiders
AREV Life Sciences Global Corp. is a Canada-based fully integrated, early-stage life science discovery company. The Company produces ingredients and formulates therapeutic interventions with plans to deliver innovation in clinical nutrition, supplements, topicals and rational drug design, based on science. Its business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company’s nutraceutical product formulations seek to be sold under its BARE and Wright and Well brands or produced for third parties on a licensed white label basis. Its BARE and Wright and Well Brands of finished products include natural health products, including cannabidiol (CBD)-infused products such as Canna-Mulsion and NaturVax, an anti- viral supplement; NaturRelax, a natural Sleep Aid; Natur Relief, an anti- inflator and pain relief product, and a line of CBD skincare products and medicinal oils and edibles.
More about the company